Paul McBarron, See Remarks at Cyclacel Pharmaceuticals, Inc. (CYCC), bought 1,886 shares at $3.32 ($6K) on 2023-12-21, disclosed to the SEC on 2023-12-26.
Open-market purchase of $6k CYCC by See Remarks. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| CYCC | BUY | 2008-05-23 | $4K | — | Filing → |